How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,969 results for

"covid 19" OR "novel coronavirus"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Impact of 2019 novel coronavirus on neurological and cerebrovascular disorders: a systematic review and meta-analysis

Impact of 2019 novel coronavirus on neurological and cerebrovascular disorders: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

162. Cytokine adsorption devices for treating respiratory failure in people with COVID-19

. • Efficacy of HA330 haemoperfusion in critically ill patients with severe COVID-19 (HA- COVID19). Trials identifier: TCTR20200409006. Status: pending (not yet recruiting). Indication: COVID-19, ARDS. Devices: HA330 haemoperfusion. Date: 1 May 2021. Country: Thailand. • CytoSorb in treating critically ill hospitalized adult patients with novel coronavirus pneumonia (COVID-19). Trials identifier: ChiCTR2000030475. Status: prospective registration. Indication: novel coronavirus pneumonia (COVID-19). Devices (...) Cytokine adsorption devices for treating respiratory failure in people with COVID-19 Cytokine adsorption devices for treating respiratory failure in people with COVID-19 Medtech innovation briefing Published: 21 May 2020 www.nice.org.uk/guidance/mib217 pathways Summary Summary • The technologies technologies described in this briefing are cytokine adsorption devices. They are for reducing blood levels of cytokines in people with COVID-19 and respiratory failure. • The innovative aspects

2020 National Institute for Health and Clinical Excellence - Advice

163. COVID-19 Updates and Information

COVID-19 Updates and Information UPDATES & INFORMATION | Powered by EBSCO ") //--> Google Translate User Login Username * Password * × Google Translate Powered by EBSCO menu Site Search Search Options Item request has been placed! Item request cannot be made. Processing Request Coronavirus Guidelines for America Workflow: Published Global News Updates Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 17th 2020 Mar 17th 2020 Mar 17th 2020 Mar 17th 2020 Mar 16th 2020 US (...) State Government News & Alerts Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 CDC Top Coronavirus (COVID-19) Updates Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 18th 2020 Mar 17th 2020 Mar 17th 2020 Mar 15th 2020 Mar 14th 2020 Mar 14th 2020 Mar 14th 2020 CIDRAP Maps & Visuals (Johns Hopkins) (HealthMap) (University of Washington) (University of Virginia) (WHO) (CDC) (ECDC) (Kaiser Family Foundation

2020 DynaMed Plus

164. COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD)

Follow Share Related Summaries Overview Coronavirus Disease 2019 (COVID-19) is an acute respiratory disease caused by novel coronavirus SARS-CoV-2 ( ) patients with existing conditions can be more susceptible to COVID-19 and are likely to experience more severe illness, including patients with , patients on , and those living with a associated with increased in-hospital mortality in patients with COVID-19; kidney abnormalities may include proteinuria, hematuria, elevated serum creatinine, elevated (...) Nephrol 20200323 review of indications for prevention and management of COVID-19 in ambulatory dialysis patients can be found in review of the novel coronavirus 2019 epidemic and kidneys can be found in reviews of COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can be found in MEDLINE Search to search MEDLINE for (COVID-19 Kidney) with targeted search (Clinical Queries), click , , or Patient Information handout on staying safe during dialysis and COVID-19

2020 DynaMed Plus

165. COVID-19 and Pregnant Patients

COVID-19 and Pregnant Patients COVID-19 and Pregnant Patients You need to enable JavaScript to run this app. Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow. Subscribe Already subscribed? Specialties 0 English COVID-19 and Pregnant Patients Follow Share Follow Share Related Summaries Overview COVID-19 infection (coronavirus disease 2019) is an acute respiratory disease caused by novel coronavirus SARS-CoV-2 ( ) many affect (...) can be considered with use of proper hand washing and other preventative measures to decrease risk of exposure for infant for mother/infant pairs who are temporarily separated, mothers who wish to breastfeed should be encouraged to express their breastmilk to establish and maintain milk supply and expressed milk should be fed to newborn by a healthy caregiver General Information Description COVID-19 infection (coronavirus disease 2019 ) is an acute respiratory disease caused by novel coronavirus

2020 DynaMed Plus

166. COVID-19 and Cardiovascular Disease Patients

with a novel coronavirus SARS-CoV-2 ( ) PubMed 32201335 Journal of the American College of Cardiology J Am Coll Cardiol 20200318 patients with preexisting cardiovascular disease may be , and may be at , especially when patients present with elevated troponin T levels, where mortality may be three-fold higher (69.4% vs. 23%) compared to those without cardiovascular disease patients who have COVID-19 may be at risk of developing , especially and arrhythmias; acute myocardial injury may be more common (...) of electrolyte imbalance may mitigate toxicity General Information Description Coronavirus Disease 2019 (COVID-19) disease is an acute respiratory disease caused by an infection with novel coronavirus SARS-CoV-2 ( ) PubMed 32201335 Journal of the American College of Cardiology J Am Coll Cardiol 20200318 patients with preexisting cardiovascular disease may be more susceptible to COVID-19 infection may be at increased risk of adverse outcomes due to direct and indirect effects of COVID-19 on cardiovascular

2020 DynaMed Plus

167. COVID-19 and Patients With Cancer

COVID-19 and Patients With Cancer COVID-19 and Patients With Cancer You need to enable JavaScript to run this app. Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow. Subscribe Already subscribed? Specialties 0 English COVID-19 and Patients With Cancer Follow Share Follow Share Related Summaries Overview Coronavirus Disease 2019 (COVID-19) is an acute respiratory disease caused by novel coronavirus SARS-CoV-2 ( ) cancer patients may (...) be at for developing severe COVID-19, including those receiving chemotherapy, or who received chemotherapy ≤ 3 months receiving extensive radiation therapy who received bone marrow or stem cell transplantation ≤ 6 months, or still treated with immunosuppressive drugs with some types of hematologic cancer that damages immune system (such as chronic leukemia, lymphoma, or myeloma), even if they did not receive treatment with impaired immune system due to leukocytopenia, low immunoglobulin levels, or long-lasting

2020 DynaMed Plus

168. COVID-19 and Special Populations

by an infection with a novel coronavirus SARS-CoV-2 ( ) patients who have COVID-19 may be at risk of developing cardiac complications, especially acute cardiac injury and arrhythmias; acute myocardial injury may be more common in patients with preexisting cardiovascular disease and may be associated with increased morbidity and mortality clinical presentation and diagnosis of COVID-19 in patients with preexisting cardiovascular disease or COVID-19-related myocardial injury diagnosis of COVID-19 may (...) disorder report any cessation to non-neurological healthcare professionals as well if considering cessation in patient with myasthenia gravis or NMO spectrum disorder, first discuss with neurology team Reference - ABN guidance on COVID-19 for people with neurological conditions ( ) Pregnancy COVID-19 infection (coronavirus disease 2019) is an acute respiratory disease caused by novel coronavirus SARS-CoV-2 many physiologic and anatomic changes of pregnancy affect the respiratory system and increase

2020 DynaMed Plus

169. Covid-19: Risk for transmission of viral infection during treatment with nebuliser or high-flow nasal cannula

Covid-19: Risk for transmission of viral infection during treatment with nebuliser or high-flow nasal cannula Risk for transmission of viral infection during treatment with nebuliser or high-flow nasal cannula We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Risk for transmission of viral infection during treatment with nebuliser or high-flow nasal (...) : a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. Heinzerling A, Stuckey MJ, Scheuer T, Xu K, Perkins KM, Resseger H, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep 2020;69:472-6. Loeb M, McGeer A, Henry B, Ofner M, Rose D, Hlywka T, et al. SARS among critical care nurses, Toronto. Emerg Infect Dis 2004;10:251-5. Raboud J, Shigayeva

2020 Swedish Council on Technology Assessement

170. Covid-19: Effectiveness of non-invasive ventilation in the treatment of acute respiratory failure due to coronavirus

-ncov’:ti,ab,kw 278 5. ‘2019ncov’:ti,ab,kw 0 6. ‘2019 ncov’:ti,ab,kw 278 7. ‘covid-19’:ti,ab,kw 398 8. ‘covid19’:ti,ab,kw 1 9. ‘sars-cov-2':ti,ab,kw 184 10. ‘covid’:ti,ab,kw 402 11. ‘ncov’:ti,ab,kw 291 12. ‘novel coronavirus’:ti,ab,kw 815 13. ‘new coronavirus’:ti,ab,kw 127 14. ‘coronavirus 2019’:ti,ab,kw 163 15. ‘sars coronavirus 2’:ti,ab,kw 2 16. 1 OR 2 OR […] 15 1 330 17. ‘severe acute respiratory syndrome’/exp 8 191 18. ‘sars coronavirus’/exp 4 636 19. ‘severe acute respiratory syndrome’:ti,ab,kw (...) Covid-19: Effectiveness of non-invasive ventilation in the treatment of acute respiratory failure due to coronavirus Effectiveness of non-invasive ventilation in the treatment of acute respiratory failure due to coronavirus We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Effectiveness of non-invasive ventilation in the treatment of acute

2020 Swedish Council on Technology Assessement

171. Covid-19: Risk for transmission of viral infection during treatment with non-invasive ventilation using CPAP or BiPAP

’:ti,ab,kw 39 4. ‘2019-ncov’:ti,ab,kw 278 5. ‘2019ncov’:ti,ab,kw 0 6. ‘2019 ncov’:ti,ab,kw 278 7. ‘covid-19’:ti,ab,kw 398 8. ‘covid19’:ti,ab,kw 1 9. ‘sars-cov-2':ti,ab,kw 184 10. ‘covid’:ti,ab,kw 402 11. ‘ncov’:ti,ab,kw 291 12. ‘novel coronavirus’:ti,ab,kw 815 13. ‘new coronavirus’:ti,ab,kw 127 14. ‘coronavirus 2019’:ti,ab,kw 163 15. ‘sars coronavirus 2’:ti,ab,kw 2 16. 1 OR 2 OR […] 15 1 330 17. ‘severe acute respiratory syndrome’/exp 8 191 18. ‘sars coronavirus’/exp 4 636 19. ‘severe acute (...) ’ OR ‘noninvasive’) NEAR/3 ‘ventilation’):ti,ab,kw 13 867 61. 31 OR 32 OR […] 60 85 368 Final 30 AND 61 175 Cochrane Library via Wiley 200323 Non-invasiv ventilation for patients with COVID-19, SARS or MERS Search terms Items found Population: 1. "severe acute respiratory syndrome coronavirus 2":ti,ab 0 2. “2019 nCov”:ti,ab 2 3. 2019nCoV:ti,ab 0 4. “2019-nCov”:ti,ab 2 5. “CoVID-19”:ti,ab 2 6. CoVID19:ti,ab 0 7. SARS-CoV-2:ti,ab 0 8. CoVid:ti,ab 2 9. nCov:ti,ab 18 10. “novel coronavirus”:ti,ab 14 11. “new

2020 Swedish Council on Technology Assessement

172. Covid-19: Impact on coagulation due to coronavirus

Covid-19: Impact on coagulation due to coronavirus Impact on coagulation due to coronavirus We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Impact on coagulation due to coronavirus Share: Reading time approx. 5 minutes Viral infections caused by SARS-CoV-2, SARS-CoV-1 or MERS-CoV may lead to coagulation disturbances and thromboembolic complications (...) of the results presented. Identified literature We identified two relevant systematic reviews [4,5] and eleven primary studies [6-16]. One relevant systematic [17] review was assessed as having a high risk of bias and its results are not presented. Table 1. Systematic reviews with low/medium risk of bias Included studies Population Outcome Violi et al. 2020 [5] 9 cohort studies from China Patients with covid-19, severely ill and non-severe patients, total n=2 109 D-dimer, platelet count, prothrombin time

2020 Swedish Council on Technology Assessement

173. Remdesivir for severe covid-19 Full Text available with Trip Pro

Remdesivir for severe covid-19 Remdesivir for severe covid-19: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Remdesivir for severe... Remdesivir for severe covid-19: a clinical practice guideline (Published 30 July 2020) Cite this as: BMJ 2020;370:m2924 Visual summary of recommendation Population Does not apply to: Disease severity Mild Moderate Severe Applies to people with at least one of: Patients (...) with mild or moderate covid-19 Pediatric patients Respiratory rate >30 Respiratory distress SpO 2 <94% on room air Requires intensive care admission This recommendation applies only to people with these characteristics: Adults with confirmed covid-19 Recommendation 1 We suggest remdesivir rather than no remdesivir in patients with severe covid-19 Usual supportive care Remdesivir or 100 mg intravenously daily for 5-10 days No remdesivir Strong All or nearly all informed people would likely want usual

2020 BMJ Rapid Recommendations

174. Novel coronavirus (2019-nCoV)

Novel coronavirus (2019-nCoV) Novel coronavirus (2019-nCoV) - Wikipedia Novel coronavirus (2019-nCoV) From Wikipedia, the free encyclopedia Virus causing the 2019–20 Wuhan outbreak This article is about the virus. For the outbreak of this virus, see . It has been requested that the title of this article be changed to . Please see . The page should not be moved unless the discussion is closed ; summarizing the consensus achieved in support of the move. This article may be affected (...) by the following : . Information in this article may change rapidly as the event progresses. Initial news reports may be . The to this article the most current information. Please feel free to or discuss changes on the . ( January 2020 ) ( ) Novel coronavirus (2019-nCoV) of two 2019-nCoV This file has and may be deleted after Friday, 31 January 2020. (unranked): Realm : Phylum: Order: Family: Genus: Subgenus: Virus: Novel coronavirus (2019-nCoV) Wuhan, China, the epicentre of the only recorded outbreak Wuhan

2020 Wikipedia

175. COVID-19 therapy with anti-COVID-19 antibodies in convalescent serum

COVID-19 therapy with anti-COVID-19 antibodies in convalescent serum COVID-19 therapy & anti-COVID-19 antibodies in serum ') Cookie Notice This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our for more details. OK Menu Search Main navigation Utility navigation / Search navigation Search Search AAAAI Breadcrumb navigation ▸ ▸ COVID-19 therapy with anti-COVID-19 antibodies in convalescent serum | COVID-19 therapy with anti-COVID-19 (...) antibodies in convalescent serum Q: 3/26/2020 The cancer patients with Non-Hodgkins Lymphoma who have had CAR-T therapy are receiving IVIG since they are enabled to make antibodies following this therapy. What treatments are available for these patients or other patient with hypogammaglobulinemia that show severe signs of COVID-19 infection? Presumable no IVIG product presently conveys any passive antibodies to this virus. Would plasma have specific COVID-19 protective anti-viral antibodies

2020 American Academy of Allergy, Asthma & Immunology - Ask the Expert

176. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis Full Text available with Trip Pro

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis Efficacy and Safety of Corticosteroids in COVID-19 Based on Evidence for COVID-19, Other Coronavirus Infections, Influenza, Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript (...) ? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation CMAJ Actions . 2020 May 14;cmaj.200645. doi: 10.1503/cmaj.200645. Online ahead of print. Efficacy and Safety of Corticosteroids in COVID-19 Based on Evidence for COVID-19, Other

2020 EvidenceUpdates

177. COVID-19

COVID-19 Coronavirus disease 2019 (COVID-19) - Symptoms, diagnosis and treatment | BMJ Best Practice     Search  Search Select language Coronavirus disease 2019 (COVID-19) Last reviewed: February 2020 Last updated: March 2020 Important updates 12 Mar 2020 WHO declares COVID-19 outbreak a pandemic The World Health Organization (WHO) formally declared the COVID-19 outbreak a pandemic on 11 March 2020. "WHO has been assessing this outbreak around the clock and we are deeply concerned both (...) by the alarming levels of spread and severity, and by the alarming levels of inaction," said WHO chief Tedros Adhanom Ghebreyesus during a press briefing. "We have therefore made the assessment that COVID-19 can be characterised as a pandemic. Describing the situation as a pandemic does not change WHO’s assessment of the threat posed by this virus. It doesn’t change what WHO is doing, and it doesn’t change what countries should do," he said. This is the first pandemic to be caused by a coronavirus

2020 BMJ Best Practice

178. Prince Edward Island guidelines for the management and control of COVID-19

of a Case 7 Treatment of a Case 7 Management of Contacts 7 Preventative Measures 8 Infection Prevention and Control in the Community 8 Infection Prevention and Control in the Healthcare Facility 8 Early Recognition and Source Control 9 Application of Routine Practices and Additional Precautions 9 Infection Prevention and Control Guidelines 10 References 11 Appendix A: Novel Coronavirus (COVID-19) Testing 12 Appendix B- Public Health Follow-up 13 Appendix C: Case Report Form 16 Appendix D: Symptom Diary (...) Health Agency of Canada travel notice website: https://www.canada.ca/en/public-health/services/diseases/2019- novel-coronavirus-infection/health-professionals/covid-19-affected-areas-list.html 7 Close contact is defined as a person who provided care for the patient, including health care workers, family members or other caregivers, or who had other similar close physical contact or who lived with or otherwise had close prolonged contact with a probable or confirmed case while the case was ill. 8

2020 CPG Infobase

179. COVID-19 recommendations during airway manipulation

mortality rate is estimated at 2 – 4%. (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ This guidance focuses on the management of the airway (also open suctioning of respiratory tract, bronchoscopy, and cardiopulmonary resuscitation) for patients with known or suspected COVID-19. Screening, contact precautions and general care of these patients prior to the need for airway manipulation are dealt with at length in other reports and we suggest reviewing the following (...) /governance-and-committees/asa-committees/committee- on-occupational-health/coronavirus 6. https://www.apsf.org/news-updates/perioperative-considerations-for-the-2019-novel- coronavirus-COVID-19/ 7. Br J Anaesth. 2020 Feb 27. pii: S0007-0912(20)30098-2. doi: 10.1016/j.bja.2020.02.008. [Epub ahead of print] 8. Lancet Respir Med. 2020 Feb 24. pii: S2213-2600(20)30084-9. doi: 10.1016/S2213- 2600(20)30084-9. [Epub ahead of print] 9. Caputo KM, Byrick R, Chapman MG, Orser BJ, Orser BA (2006) Intubation of SARS

2020 CPG Infobase

180. Coronavirus disease 2019 (COVID-19): Management in hospitalized adults

Coronavirus disease 2019 (COVID-19): Management in hospitalized adults UpToDate It seems to us that you have your JavaScript disabled on your browser. JavaScript is required in order for our site to behave correctly. Please enable JavaScript to use our site.

2020 UpToDate

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>